A Dutch medtech company, AMT Medical, has raised significant funds to expedite its heart bypass solution. The company focuses on a system that performs coronary bypass surgery without requiring a large chest incision or stopping the heart. Additional insights suggest that the firm is exploring broader applications and integration with robotics, potentially impacting surgical practices worldwide.
Recent reports confirm that similar medtech funding initiatives across Europe highlight robust investor interest in innovative cardiac treatments. Competing publications mention that this funding round reflects an industry trend supporting firms that aim to provide less invasive alternatives to traditional procedures, with several investors actively participating in these developments.
Funding Details and Investment Stakeholders
AMT Medical completed a Series B funding round that totaled €22M, including a €5M contribution from Invest-NL. The round was led by Bender Analytical Holding and supported by Oost NL, the European Innovation Council, and various informal investors. Discussions among stakeholders underline the strategic role that capital plays in scaling clinical research and preparing for market entry.
Innovative Procedure and Commercial Prospects
The company’s Elana Heart Bypass technology employs a patented clip and laser system to connect blood vessels without traditional sutures. This method facilitates minimally invasive procedures and is designed to work with surgical robots, offering broader treatment options for patients unsuitable for open-heart surgery.
Clinical applications of the technology are being pursued in partnership with UMC Utrecht, with ongoing studies at Antonius Hospital Nieuwegein and the German Heart Centre in Berlin.
We see AMT as a game changer that not only improves patient outcomes, but also reduces the pressure on the healthcare system.
This technology makes minimally invasive cardiac surgery more accessible, safer and scalable – exactly the kind of system innovation we believe in.
The current financing supports efforts such as obtaining the CE marking and expanding clinical studies internationally. The investment offers a pathway to quickly implement new surgical techniques while addressing the need for improved patient recovery times and operational efficiencies in cardiac care.
